BRAIN Biotech AG (XTER:BNN) FCF Margin % : -3.72% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is BRAIN Biotech AG FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. BRAIN Biotech AG's Free Cash Flow for the three months ended in Mar. 2024 was €-0.54 Mil. BRAIN Biotech AG's Revenue for the three months ended in Mar. 2024 was €14.47 Mil. Therefore, BRAIN Biotech AG's FCF Margin % for the quarter that ended in Mar. 2024 was -3.72%.

As of today, BRAIN Biotech AG's current FCF Yield % is -3.29%.

The historical rank and industry rank for BRAIN Biotech AG's FCF Margin % or its related term are showing as below:

XTER:BNN' s FCF Margin % Range Over the Past 10 Years
Min: -42.04 Med: -22.26 Max: -3.34
Current: -3.34

During the past 9 years, the highest FCF Margin % of BRAIN Biotech AG was -3.34%. The lowest was -42.04%. And the median was -22.26%.

XTER:BNN's FCF Margin % is ranked worse than
65.27% of 1529 companies
in the Chemicals industry
Industry Median: 1.2 vs XTER:BNN: -3.34

BRAIN Biotech AG FCF Margin % Historical Data

The historical data trend for BRAIN Biotech AG's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BRAIN Biotech AG FCF Margin % Chart

BRAIN Biotech AG Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

FCF Margin %

Get a 7-Day Free Trial

-25.98

-19.95

-13.46

-15.28

-12.39

BRAIN Biotech AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-26.07	8.14	1.75	-20.80	-3.72

Competitive Comparison of BRAIN Biotech AG's FCF Margin %

For the Specialty Chemicals subindustry, BRAIN Biotech AG's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BRAIN Biotech AG's FCF Margin % Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's FCF Margin % distribution charts can be found below:

* The bar in red indicates where BRAIN Biotech AG's FCF Margin % falls into.

BRAIN Biotech AG FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

BRAIN Biotech AG's FCF Margin for the fiscal year that ended in Sep. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Sep. 2023 )	/	Revenue (A: Sep. 2023 )
	=	-6.856	/	55.335
	=	-12.39 %

BRAIN Biotech AG's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-0.539	/	14.474
	=	-3.72 %

BRAIN Biotech AG FCF Margin % Related Terms

Thank you for viewing the detailed overview of BRAIN Biotech AG's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

BRAIN Biotech AG (XTER:BNN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BRAIN Biotech AG (XTER:BNN) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

BNN:Germany BNN:Germany BNN:Germany

Address

Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673

Website

https://www.brain-biotech.com

BRAIN Biotech AG is a technology company in the field of industrial biotechnology. It serves the chemical and consumer goods industries. The company develops novel biological ingredients such as enzymes, biocatalysts, and bioactive natural compounds. The company's segments include, BioProducts, BioScience and BioIncubator. Majority of the revenue is generated from its BioProducts segment which comprises of the product business with enzymes and other proteins for specific segments of the food industry. Geographically, the company generates majority of the revenue from United States of America and also has presence in other markets such as, Germany, France, United Kingdom and Netherlands.

Executives

Dr. Michael Majerus	Supervisory Board
Dr. Georg Kellinghusen	Supervisory Board
Michael Schneiders	Board of Directors
Adriaan Moelker	Board of Directors
Lukas Linnig	Board of Directors

BRAIN Biotech AG (XTER:BNN) Headlines

No Headlines